Urinary Incontinence Treatment Drugs Market Size and Trends

Urinary Incontinence Treatment Drugs Market, By Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, Other Incontinence Type), By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Oct 2023

Code : CMI4400

Pages :180

Formats :

Excel and PDF

Industry : Pharmaceutical

Urinary Incontinence Treatment Drugs MarketSize and Trends

Global urinary incontinence treatment drugs market is estimated to be valued at US$ 4.41 Bn in 2023, and is expected to exhibit a CAGR of 3.4% during the forecast period (2023-2030).

Urinary incontinence (UI), or involuntary urine loss, is a highly prevalent issue that no one wants to discuss. Many people are too embarrassed to seek help because of the stigma that surrounds it. However, most illnesses that cause UI can be treated medically or through alternative means. Rising prevalence of urinary incontinence, growing geriatric population, and increasing developments by key market players are expected to boost the global urinary incontinence treatment drugs market growth over the forecast period.

Figure 1. Global Urinary Incontinence Treatment Drugs Market Share (%), By Incontinence Type, 2023

Increasing number of regulatory approval for drugs: Increasing number of regulatory approval for drugs boosts the global urinary incontinence treatment drugs market growth. For instance, in December 2020, Urovant Sciences, a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved the New Drug Application (NDA) for 75 mg GEMTESA (vibegron), a beta-3 adrenergic receptor (β3) agonist, once daily for the treatment of overactive bladder (OAB). The symptoms of urge urinary incontinence (UUI) includes urgency and frequency of urination in adults. This approval marks the first new brand-name oral OAB drug approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences.
Increasing prevalence of urinary incontinence: Increasing prevalence of urinary incontinence is expected to boost demand for urinary incontinence treatment drugs, and this is expecetd to drive the global urinary incontinence treatment drugs market growth. For instance, in September 2021, according to a research study published by International Journal of Obstetrics and Gynaecology, , 24,985 women (mean age 41.9 years) were considered for the study. The follow-up rate was 55.5%, the mean follow-up time was 3.7 years. The standardized incidences of urinary incontinence (UI), stress urinary incontinence (SUI), urge urinary incontinence (UUI), and mixed urinary incontinence (MUI) were 21.2, 13.1, 3.0, and 5.1 per 1000 person-years, respectively.